ClinicalTrials.gg
Not yet recruitingNCT07751315Updated Aug 7, 2026

A Study of QLS2404 Injection in Healthy Participants and Participants With Rheumatic Autoimmune Diseases

A Phase 1 interventional study of Ia:QLS2404 very low dose and Ia:QLS2404 low dose in Systemic Lupus Erythematosus and Primary Sjögren's Syndrome, sponsored by Qilu Pharmaceutical Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-07.

Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 266 studies in Lupus Erythematosus, Systemic with a site in China — 168 open to participants now, 191 under way, 22 of them phase 3. Lupus Erythematosus, Systemic · China.

Planned enrollment
87th of 245
64 · median 36
Started
2026
with 55 others
Phase 1
109 of 266
85 open now
Primary completion
2027-11
later than 122 of 190 live
Registered
261st of 266
by date

Among the 266 studies in Lupus Erythematosus, Systemic with a site in China, this one is the 87th largest by planned enrollment of the 245 interventional ones that give a count, is one of 56 that started in 2026, is one of 109 in phase 1, reaches primary completion later than 122 of the 190 other live ones, and was the 261st registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

168 of the 266 studies in Lupus Erythematosus, Systemic with a site in China are open now. Recruiting first, the newest first:

163 more — sign in →

All 168 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 266 studies in Lupus Erythematosus, Systemic with a site in China, or all of them as a file.
02

Study summary

This study consists of a randomized, double-blind, placebo-controlled Phase Ia part and an open-label Phase Ib part. The Phase Ia part is a single ascending-dose study of subcutaneous QLS2404 Injection in healthy participants, designed to evaluate the safety and tolerability of QLS2404 Injection in healthy participants. The Phase Ib part is a multiple ascending-dose study of subcutaneous QLS2404 Injection in participants with systemic lupus erythematosus and primary Sjögren's syndrome, designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of QLS2404 Injection.

Read the detailed description

The Phase Ia single-dose ascending stage will include five dose groups. The study plans to enroll 40 adult healthy participants, with 8 participants in each dose group, who will be randomized in a 3:1 ratio to receive QLS2404 Injection or placebo. Dose escalation will be conducted sequentially from the initial dose to higher dose levels in accordance with the dose-escalation principle.

During the study, a Safety Monitoring Committee (SMC), composed of the investigators, the sponsor, or sponsor-designated personnel, will review the safety data generated during the trial. After the last participant in each dose group has completed the 14-day tolerability observation period following dosing, the SMC will review the safety data of participants in each cohort and conduct an integrated assessment of the available pharmacokinetic (PK) and pharmacodynamic (PD) data. The SMC will then provide recommendations regarding dose escalation or, if necessary, adjustments to the dose-escalation scheme.

The Phase Ib part will be a multiple ascending-dose study of subcutaneous QLS2404 Injection in participants with systemic lupus erythematosus (SLE) and primary Sjögren's syndrome (pSS), designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of QLS2404 Injection. Three dose groups are planned, with approximately 24 participants to be enrolled in total and 8 participants in each dose group. All participants will receive three subcutaneous doses of QLS2404 Injection, administered at 4-week intervals. Each dose group must include at least 6 participants with SLE, and the study will be conducted in strict accordance with the dose-escalation principle.

03

Conditions studied

  • Systemic Lupus Erythematosus
  • Primary Sjögren's Syndrome

Keywords

  • systemic lupus erythematosus
  • primary Sjögren's syndrome
  • SLE
  • pSS
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ia
  • Participants who understand and comply with the study procedures and methods, voluntarily participate in this trial, provide written , and are able to complete the study in accordance with the protocol requirements.
  • Male or female participants aged ≥18 and ≤45 years on the date of signing the informed consent form.
  • (BMI) at screening ≥19 kg/m² and ≤26 kg/m², with body weight ≥45 kg.
  • Participants assessed by the investigator to be in good health based on medical history, physical examination, vital signs, and laboratory test results during the screening period.
  • Ib
  • Participants who voluntarily sign the informed consent form before the initiation of any study-related procedures, are able to communicate effectively with the investigator, understand and are willing to strictly comply with the requirements of this clinical study protocol, and complete the study.
  • Male or female participants aged ≥18 and ≤65 years at the time of signing the informed consent form.
  • Body mass index (BMI) at screening ≥18 kg/m² and ≤35 kg/m².
  • Participants with systemic lupus erythematosus must meet the 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria for SLE and be diagnosed with systemic lupus erythematosus; the diagnosis must have been established at least 6 months prior to signing the informed consent form.
  • Participants with primary Sjögren's syndrome must meet the 2016 ACR/EULAR classification criteria for primary Sjögren's syndrome and be diagnosed with primary Sjögren's syndrome; the diagnosis must have been established at least
  • months prior to signing the informed consent form.

Exclusion criteria

Exclusion Criteria:

  • Ia
  • interval corrected by (ECG) ≥450 ms at screening; and any other ECG abnormalities that, in the investigator's opinion, may pose an unacceptable risk to the participant.
  • Participants with a history of, or current, chronic or serious diseases of the musculoskeletal, neuropsychiatric, endocrine, circulatory, respiratory, digestive, urinary, reproductive, or other systems, who are considered by the investigator to be unsuitable for participation in the clinical trial.
  • Participants who have lost more than 400 mL of blood due to blood donation or other reasons within 3 months prior to screening.
  • Participants who are considered by the investigator to be unsuitable for participation in the clinical trial or unable to complete this study for other reasons.
  • Ib
  • Any disease or condition that, in the investigator's opinion, may interfere with the evaluation of study drug efficacy, participant safety assessment, or interpretation of study results.
  • Participants who have participated in any cell therapy, gene therapy clinical trial, or medical device clinical trial within 3 months prior to screening.
  • Participants who have received Bacillus Calmette-Guérin (BCG) vaccination within 1 year prior to screening.
  • Participants who have received any within 1 month prior to screening or who require live attenuated vaccination during study participation.
  • Participants who are breastfeeding or have a positive serum human chorionic gonadotropin (hCG) test during the screening period.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    Ia treatment group 1

    Drug: Ia:QLS2404 very low dose

  • Experimental
    Ia treatment group 2

    Drug: Ia:QLS2404 low dose

  • Experimental
    Ia treatment group 3

    Drug: Ia:QLS2404 middle dose

  • Experimental
    Ia treatment group 4

    Drug: Ia:QLS2404 high dose

  • Experimental
    Ia treatment group 5

    Drug: Ia:QLS2404 Max dose

  • Experimental
    Ib treatment group 1

    Drug: Ib:QLS2404 low dose

  • Experimental
    Ib treatment group 2

    Drug: Ib:QLS2404 middle dose

  • Experimental
    Ib treatment group 3

    Drug: Ib:QLS2404 high dose

Interventions

  • DrugIa:QLS2404 very low dose

    a single subcutaneous dose of QLS2404 Injection in healthy participants

  • DrugIa:QLS2404 low dose

    a single subcutaneous dose of QLS2404 Injection in healthy participants

  • DrugIa:QLS2404 middle dose

    a single subcutaneous dose of QLS2404 Injection in healthy participants

  • DrugIa:QLS2404 high dose

    a single subcutaneous dose of QLS2404 Injection in healthy participants

  • DrugIa:QLS2404 Max dose

    a single subcutaneous dose of QLS2404 Injection in healthy participants

  • DrugIb:QLS2404 low dose

    multiple subcutaneous doses of QLS2404 Injection in participants with systemic lupus erythematosus (SLE) and primary Sjögren's syndrome (pSS)

  • DrugIb:QLS2404 middle dose

    multiple subcutaneous doses of QLS2404 Injection in participants with systemic lupus erythematosus (SLE) and primary Sjögren's syndrome (pSS)

  • DrugIb:QLS2404 high dose

    multiple subcutaneous doses of QLS2404 Injection in participants with systemic lupus erythematosus (SLE) and primary Sjögren's syndrome (pSS)

06

What researchers measure

Primary outcomes

  1. Ia:the safety and tolerability of a single subcutaneous dose of QLS2404 Injection in healthy participants

    Number of participants with Adverse events and Serious adverse events

    Time frame: from the first single subcutaneous Inject of QLS2404 up to Day85

  2. Ib:To evaluate the Adverse events of multiple subcutaneous injections of QLS2404 Injection in participants with systemic lupus erythematosus (SLE) and primary Sjögren's syndrome (pSS).

    Number of participants with Adverse events and Serious adverse events

    Time frame: from the first single subcutaneous Inject of QLS2404 up to Day141.

Secondary outcomes

  1. Ia Outcome 1:To evaluate the pharmacokinetic (PK) characteristics of a single subcutaneous injection of QLS2404 Injection in healthy participants.

    include serum QLS2404 concentrations such as peak plasma concentration (Cmax)

    Time frame: from the first single subcutaneous Inject of QLS2404 up to Day85

  2. Ia Outcome 2:To evaluate the pharmacodynamic (PD) characteristics of a single subcutaneous injection of QLS2404 Injection in healthy participants.

    assessments include serum levels of IgM, IgG, and IgA at each scheduled time point before and after dosing

    Time frame: from the first single subcutaneous Inject of QLS2404 up to Day85.

  3. Ia Outcome 3:To evaluate the immunogenicity of a single subcutaneous injection of QLS2404 Injection in healthy participants.

    include the incidence and titers of anti-drug antibodies (ADAs) against QLS2404 Injection in healthy participants, and the incidence of neutralizing antibodies (NAbs), if data permit.

    Time frame: from the first single subcutaneous Inject of QLS2404 up to Day85

  4. Ib Outcome 1:Applicable to participants with SLE: The proportion of participants with a ≥ 4-point decrease from baseline in SLE Disease Activity Index 2000 (SLEDAI-2K).

    SLEDAI-2K Description: The minimum SLEDAI-2K score is 0, and the maximum theoretical SLEDAI-2K score is 105. A score of 0 indicates no active disease; a greater score indicates higher systemic lupus erythematosus disease activity.

    Time frame: from the first subcutaneous Inject of QLS2404 up to Day141.

  5. Ib Outcome 2:To evaluate the pharmacokinetic (PK) characteristics of multiple subcutaneous injections of QLS2404 Injection in participants .

    Serum drug concentrations after administration peak plasma concentration (Cmax)

    Time frame: from the first subcutaneous Inject of QLS2404 up to Day141

  6. Ib Outcome 3:Evaluate the PD characteristics of multiple subcutaneous injections of QLS2404 Injection in participants with SLE and pSS;

    Serum IgM, IgG, and IgA levels at each assessment time point, and the percentage change from baseline;

    Time frame: from the first subcutaneous Inject of QLS2404 up to Day141

  7. Ib Outcome 4:Evaluate the immunogenicity of multiple subcutaneous injections of QLS2404 Injection in participants with SLE and pSS;

    Incidence and titers of anti-drug antibodies (ADA) to QLS2404 Injection in participants with SLE and pSS; incidence of neutralizing antibodies (NAb), if data permit.

    Time frame: from the first subcutaneous Inject of QLS2404 up to Day141

  8. Applicable to participants with pSS: The proportion of participants with a ≥ 3-point ESSDAI

    Description: The minimum ESSDAI score is 0, and the maximum ESSDAI score is 123. A score of 0 indicates no systemic disease activity; a greater score indicates higher systemic disease activity in Sjögren's syndrome.

    Time frame: from the first subcutaneous Inject of QLS2404 up to Day141.

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Nov 2027, 14 months later.

Of 108 industry-sponsored phase 1 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 35. This study's planned 14 months is below that.

Counting every sponsor, half of 147 studies reached it within 28 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2026
First posted
Aug 7, 2026
StartEst.
Aug 11, 2026
Primary completionEst.
Nov 7, 2027
CompletionEst.
Jun 30, 2028
Last update
Aug 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07751315
Responsible party
Sponsor
First posted
Aug 7, 2026
Start date
Aug 11, 2026 (estimated)
Primary completion
Nov 7, 2027 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Aug 7, 2026

Study contacts

Ping Feng, phD
Contact
617130961@qq.com
028-85422707
Qibing Xie, phD
Contact
xqb_fsmygcp@126.com
028-85422707
Ping Feng, phD
principal investigator · West China Hospital
Qibing Xie, phD
principal investigator · West China Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion